Retatrutide Chemical Structure: Formula, Sequence, and Lipidation
Direct answer: retatrutide (LY3437943) is a single 39-residue, GIP-derived peptide engineered with noncanonical amino acids and a C20 fatty-diacid side chain attached through a linker at lysine 17. Its “triple agonist” description refers to measured activity at GIP, GLP-1, and glucagon receptors; it does not mean that three peptides are blended together.
What makes up the retatrutide structure?
The structure has to be read in layers. The peptide backbone defines residue order. Substituted residues tune enzymatic stability and receptor pharmacology. A linker and lipid side chain add another identity layer that cannot be represented by the one-letter amino-acid sequence alone. Salt form, terminal chemistry, and counterions belong in the material record as separate fields.
The original discovery paper describes LY3437943 as a single triple-receptor agonist developed through sequence engineering and tested across receptor assays, animal models, and first-in-human work (Coskun et al., PubMed 35985340). A later structural study reports noncanonical residues at positions 2, 13, and 20 and a fatty-diacid moiety connected through lysine 17, while cryo-EM structures show the peptide bound separately to GLP-1R, GIPR, and GCGR (Li et al., PubMed 39019866).
A structure record needs more than one field
| Structural layer | What should be recorded | Evidence that can support it |
|---|---|---|
| Peptide backbone | Residue order and length | Sequence specification, peptide mapping, tandem MS |
| Noncanonical residues | Exact residue identity and position | Synthesis record, reference comparison, site-specific MS |
| Lipidation | Linker, fatty-diacid identity, and attachment site | Intact mass plus site-localizing fragments |
| Terminal chemistry | Free acid, amide, or another defined terminus | Specification and structure-sensitive analysis |
| Salt or counterion | Reported material form | Ion analysis or a lot-specific specification |
| Receptor activity | Assay system, receptor, endpoint, and potency | Validated functional assay—not chemical structure alone |
This layered reading follows the same principle explained in the peptide salt-form guide: sequence identity, counterion, chromatographic purity, and quantitative content are different questions. The cagrilintide modification-mapping guide provides another example of why an intact mass is only the first structural check.
Does the molecular formula settle the identity?
No. A molecular formula counts elements but does not encode residue order, attachment site, or stereochemistry. It may also change with the record's salt and protonation conventions. PubChem currently provides a retatrutide sodium-salt record with a computed structure and formula, but that database entry must be cited with its exact material label rather than treated as every possible form of retatrutide (PubChem CID 171934787).
For laboratory identity work, a matching calculated mass is useful but not sufficient. Isomers, misplaced lipidation, sequence variants, and some linkage differences can evade a simple mass-only conclusion. The peptide stereochemistry guide explains why equal mass does not guarantee equal structure.
Why the lipid side chain matters
The C20 fatty-diacid moiety is part of the defined molecule, not an optional excipient. It changes hydrophobicity and supports albumin association, which alters pharmacokinetic behavior. It also changes analytical behavior: sample recovery, chromatographic retention, and ionization can differ from an unmodified peptide. A receptor assay measures signaling in a particular system; it does not independently verify that the correct lipid is attached at the correct residue.
The structural cryo-EM study compared how retatrutide engages each of the three receptors and paired those structures with cAMP assays and receptor mutagenesis. Those results support receptor-specific interaction models, but they do not turn the molecule into a generic “GLP-3.” GIPR, GLP-1R, and GCGR remain three distinct receptors with separate assay records.
How this applies to a research-material record
A defensible record for Retatrutide research material should identify the intended molecular form and separate identity evidence from purity and content. Related Tirzepatide research material and Semaglutide research material are also lipidated peptides, but their sequences, attachment positions, and receptor profiles are not interchangeable. The GLP-1 research collection helps locate these records; it does not establish structural equivalence.
Batch-specific statements should be tied to the matching report in the NEXTWAVE PEPTIDES COA library. If a report does not localize a modification or distinguish salt form, that limitation should remain visible.
Research limitations
Structural diagrams, database formulas, intact mass, chromatograms, receptor assays, and cryo-EM each answer different questions. The cited research describes defined reference molecules and specific experimental systems; it does not verify an unrelated commercial batch. Database annotations can change and may represent a salt rather than a neutral form. Nothing in this article provides dosing, human-use, efficacy, or safety guidance.
Frequently asked questions
Is retatrutide a blend of three peptides?
No. It is one engineered peptide with measured agonist activity at three receptor families.
How many amino-acid residues does retatrutide contain?
The published molecular design describes a 39-residue peptide backbone with additional noncanonical and lipid-linked features.
Can intact LC-MS confirm the lipid attachment site?
Intact mass can support the overall composition. Site localization normally requires informative fragments, mapping, or comparison with a suitable reference.
Is retatrutide simply another name for tirzepatide?
No. Their sequences, lipidation details, and receptor-activity profiles differ.